Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
Akebia Therapeutics (Nasdaq: AKBA) announced its participation in the 36th Annual Piper Sandler Healthcare Conference. CEO John Butler will lead a Fireside Discussion on December 3rd at 10:30 AM EST. The conference is scheduled for December 3-5, 2024 in New York. A webcast of the presentation will be available on Akebia's investor relations website for six months following the event. Akebia focuses on developing treatments for people affected by kidney disease.
Akebia Therapeutics (Nasdaq: AKBA) ha annunciato la sua partecipazione alla 36ª Conferenza Sanitaria Annuale Piper Sandler. Il CEO John Butler condurrà una Discussione Informale il 3 dicembre alle 10:30 AM EST. La conferenza è programmata dal 3 al 5 dicembre 2024 a New York. Una registrazione della presentazione sarà disponibile sul sito web delle relazioni con gli investitori di Akebia per sei mesi dopo l'evento. Akebia si concentra sullo sviluppo di trattamenti per le persone affette da malattie renali.
Akebia Therapeutics (Nasdaq: AKBA) anunció su participación en la 36ª Conferencia Anual de Salud Piper Sandler. El CEO John Butler liderará una Conversación junto a la Chimenea el 3 de diciembre a las 10:30 AM EST. La conferencia está programada del 3 al 5 de diciembre de 2024 en Nueva York. Una transmisión de la presentación estará disponible en el sitio web de relaciones con inversores de Akebia durante seis meses después del evento. Akebia se enfoca en desarrollar tratamientos para las personas afectadas por enfermedades renales.
Akebia Therapeutics (Nasdaq: AKBA)는 제36회 파이퍼 샌들러 건강 회의에 참석한다고 발표했습니다. CEO John Butler는 12월 3일 오전 10시 30분 EST에 Fireside Discussion을 이끌 것입니다. 회의는 2024년 12월 3일부터 5일까지 뉴욕에서 열릴 예정입니다. 발표의 웹캐스트는 행사 이후 6개월 동안 Akebia의 투자자 관계 웹사이트에서 제공됩니다. Akebia는 신장 질환에 영향을 받은 사람들을 위한 치료법 개발에 집중하고 있습니다.
Akebia Therapeutics (Nasdaq: AKBA) a annoncé sa participation à la 36e Conférence Annuelle en Santé Piper Sandler. Le PDG John Butler animera une Discussion au coin du feu le 3 décembre à 10h30 EST. La conférence est prévue du 3 au 5 décembre 2024 à New York. Un webinaire de la présentation sera disponible sur le site des relations avec les investisseurs d'Akebia pendant six mois après l'événement. Akebia se concentre sur le développement de traitements pour les personnes touchées par des maladies rénales.
Akebia Therapeutics (Nasdaq: AKBA) gab die Teilnahme an der 36. jährlichen Piper Sandler Gesundheitskonferenz bekannt. CEO John Butler wird am 3. Dezember um 10:30 Uhr EST eine Fireside-Discussion leiten. Die Konferenz ist für den 3. bis 5. Dezember 2024 in New York angesetzt. Ein Webcast der Präsentation wird für einen Zeitraum von sechs Monaten nach der Veranstaltung auf der Investor-Relations-Website von Akebia verfügbar sein. Akebia konzentriert sich auf die Entwicklung von Behandlungen für Menschen, die an Nierenerkrankungen leiden.
- None.
- None.
A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com for 6 months following the conference.
The Piper Sandler Healthcare Conference will take place December 3-5, 2024 in
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-36th-annual-piper-sandler-healthcare-conference-302315009.html
SOURCE Akebia Therapeutics, Inc.
FAQ
When is Akebia Therapeutics (AKBA) presenting at the Piper Sandler Healthcare Conference 2024?
How long will the AKBA Piper Sandler Conference webcast be available?
Where can I watch Akebia Therapeutics' (AKBA) Piper Sandler Conference presentation?
What type of presentation will AKBA give at the Piper Sandler Healthcare Conference?
